HIV products account for a considerable majority of Gilead’s revenue, though one oncologic is beginning to creep up the sales ladder and an experimental drug is showing signs of effectiveness against COVID-19.
GlaxoSmithKline is undergoing a two-year process to separate into two new leading companies in the areas of biopharma and consumer healthcare.
Johnson & Johnson is concentrated on advancing the development of new products to help address pandemics and save lives, including a novel coronavirus vaccine.
Long known as a diabetes-focused company, Lilly now has the world’s leading diabetes brand in Trulicity.
Merck is cutting weight to focus on the company’s world-beating oncologic and other high-growth-potential products.
New product launches along with a disciplined focus on costs and operational efficiency have Novartis well-positioned to continue the company’s growth trajectory.
Pfizer advanced the cancer pipeline in 2019, but with the advent of the COVID-19 pandemic, the company threw its scientific strength at generating a vaccine against the novel coronovirus.
Roche is focused on finding new treatments and diagnostics that help patients live longer, better lives, and evolve the practice of medicine.
Sanofi’s new CEO, Paul Hudson, was not only faced with the task of keeping the company on a growth track, he had to account for the impact of COVID-19.
After taking a year to digest Shire, Takeda has been narrowing the company’s focus by divesting non-core products from the portfolio.